Dr Joseph Fuhr: Market Share Is Not the True Metric of Biosimilar Competition

June 6, 2017

Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, discusses biosimilar competition and its effect on market share and price.

Transcript (slightly modified)

What will predict the biosimilar market share?

Differences in various drug prices concerning various indications will depend on the number of competitors and how the originator responds to competition. If the originator responds aggressively by decreasing its price, market share of biosimilars may be low, but consumers benefit (from) lower prices and greater access. Market share is not the true metric; the real metric is how much prices have decreased in the market since biosimilars’ entry. And this underestimates the benefits, since (the) price of the originators would probably have increased without competition.

Related Content:

Interviews | Business

x